Trial Profile
A Randomized, Double-Masked, Dose-Ranging, Multi-Center, Phase II Study Comparing the Safety and Efficacy of OT-551 With Placebo to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 May 2014
Price :
$35
*
At a glance
- Drugs CPC 551 (Primary)
- Indications Dry macular degeneration
- Focus Therapeutic Use
- Acronyms OMEGA
- Sponsors Othera Pharmaceuticals
- 23 May 2014 New trial record